Chronic regular use of 2-adrenoceptor (2-AR) agonists in asthma is associated with a loss of disease control and increased risk of death. Conversely, we have found that administration of 2-AR inverse agonists results in attenuation of the asthma phenotype in an allergen-driven murine model. Besides antagonizing agonistinduced signaling and reducing signaling by empty receptors, -AR inverse agonists can also activate signaling by novel pathways. To determine the mechanism of the -AR inverse agonists, we compared the asthma phenotype in 2-AR-null and wild-type mice. Antigen challenge of 2-AR-null mice produced results similar to what was observed with chronic 2-AR inverse agonist treatment, namely, reductions in mucous metaplasia, airway hyperresponsiveness (AHR), and inflammatory cells in the lungs. These results indicate that the effects of 2-AR inverse agonists are caused by inhibition of 2-AR signaling rather than by the induction of novel signaling pathways. Chronic administration of alprenolol, a -blocker without inverse agonist properties, did not attenuate the asthma phenotype, suggesting that it is signaling by empty receptors, rather than agonist-induced 2-AR signaling, that supports the asthma phenotype. In conclusion, our results demonstrate that, in a murine model of asthma, 2-AR signaling is required for the full development of three cardinal features of asthma: mucous metaplasia, AHR, and the presence of inflammatory cells in the lungs.airway hyperresponsiveness ͉ -blocker ͉ inverse agonist ͉ mucous metaplasia ͉ inflammation